Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

707
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
707
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

209
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
209
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

678
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
678
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

215
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
215
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

317
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
317
Cancer Survival Analysis01:21

Cancer Survival Analysis

645
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
645

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Timing of Antidiabetic Medication Initiation and Risk of Cardiovascular Events and Mortality.

JAMA network open·2026
Same author

Spider Silk-Like Nanodomain Spacings Enable Mechanically Robust and Healable Elastomers with Record-High Puncture Resistance.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

Effects of Processing Parameters on the Mechanical, Thermo-Mechanical and Creep-Recovery Properties of Unidirectional Carbon Fiber Reinforced Thermoplastic Polypropylene Composites.

Polymers·2026
Same author

Distinct Oxidoreductases Orchestrate Indolethiophene Skeleton Formation and N-Hydroxylation-Mediated Bioactivation in Thienoxidolin Biosynthesis.

Angewandte Chemie (International ed. in English)·2026
Same author

Risk of major bleeding events associated with concomitant use of selective serotonin reuptake inhibitors and anti-thrombotic drugs: a nationwide case-case-time-control study.

Age and ageing·2026
Same author

Enhanced Damping-Like Torque through Strain Modulation in RuO<sub>2</sub>.

Nano letters·2026

Related Experiment Video

Updated: Jan 14, 2026

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
08:51

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Published on: September 20, 2024

2.0K

Multi-omics data improves one-year mortality prediction in acute heart failure.

Xingxing Li1, Ye Jia2, Feng Wang2

  • 1CAMS Key Laboratory of Synthetic Biology for Drug Innovation, NHC Key Laboratory of Biotechnology for Microbial Drugs and State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Tiantan Xili, Beijing 100050, China.

Clinica Chimica Acta; International Journal of Clinical Chemistry
|October 18, 2025
PubMed
Summary

Predicting mortality in acute heart failure (AHF) is improved by combining clinical data with novel plasma metabolites and gut microbes. This multi-omics approach offers a more accurate prognostic model for AHF patients.

Keywords:
Acute heart failureGut-microbiotaMetabolomicsPrognosis

More Related Videos

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

523
Author Spotlight: Advancing Alzheimer's Research &#8211; Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.7K

Related Experiment Videos

Last Updated: Jan 14, 2026

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
08:51

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Published on: September 20, 2024

2.0K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

523
Author Spotlight: Advancing Alzheimer's Research &#8211; Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.7K

Area of Science:

  • Cardiology
  • Metabolomics
  • Microbiomics

Background:

  • Acute heart failure (AHF) presents a high mortality risk, particularly in older individuals.
  • Predicting prognosis in AHF is challenging due to its complex and heterogeneous nature.
  • This study investigates plasma metabolites, gut microbiota, and clinical indicators for predicting AHF mortality.

Purpose of the Study:

  • To assess the prognostic capability of plasma metabolites and gut microbiota in predicting 1-year mortality in AHF patients.
  • To identify novel biomarkers for AHF prognosis.
  • To develop an integrated prognostic model for AHF.

Main Methods:

  • Quantified plasma trimethylamine N-oxide (TMAO) and routine clinical parameters.
  • Performed non-targeted metabolomic profiling and 16S rRNA gene sequencing for gut microbiota analysis.
  • Utilized Cox regression and ROC curves to evaluate biomarker predictive power for 1-year mortality.

Main Results:

  • N-terminal pro-B-type natriuretic peptide (NT-proBNP) showed an AUC of ~0.7; TMAO had limited predictive utility.
  • Combining NT-proBNP with age and BUN improved prognostic accuracy.
  • Identified 9 novel prognostic metabolites and 3 differential gut genera associated with AHF prognosis.
  • A multi-omics panel (NT-proBNP, age, BUN, metabolites, Faecalibacterium) achieved an AUC of 0.902.

Conclusions:

  • Multi-omics analyses revealed novel prognostic metabolites and gut microbes linked to 1-year mortality in AHF.
  • Integration of these biomarkers with clinical data offers a promising model for enhanced AHF prognosis.